GlassScriptPhysician profile
Mitchell Jarred Goldstein
NPI 1710947247
$1,004.53
in general payments reported to CMS, 2019-2025
19 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.87 · 2020: $21.05 · 2022: $102 · 2023: $98.11 · 2024: $255 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.99 |
| Education | $122.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $132.72 | 2022-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $121.61 | 2022-2025 | |
| Sobi, INC | $117.44 | 2025 | |
| Glaxosmithkline, LLC. | $106.58 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $89.04 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $72.47 | 2025 | Somatuline Depot, Onivyde |
| Astrazeneca Pharmaceuticals LP | $63.50 | 2024-2025 | Calquence, Imfinzi |
| Eisai INC. | $54.62 | 2020-2025 | |
| Gilead Sciences, INC. | $42.94 | 2023-2024 | |
| Genzyme Corporation | $32.46 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $28.48 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $24.23 | 2024 | |
| Pfizer INC. | $23.68 | 2024 | |
| Astellas Pharma US INC | $23.55 | 2023 | Xospata |
| Aveo Pharmaceuticals, INC. | $21.06 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2025 | |
| Puma Biotechnology, INC. | $16.87 | 2019 | |
| Lilly USA, LLC | $13.28 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.